RadioS Cancer Research Results

RadioS, RadioSensitizer: Click to Expand ⟱
Source:
Type:
A radiosensitizer is an agent that makes cancer cells more sensitive to the damaging effects of radiation therapy. By using a radiosensitizer, clinicians aim to enhance the effectiveness of radiation treatment by either increasing the damage incurred by tumor cells or by interfering with the cancer cells’ repair mechanisms. This can potentially allow for lower doses of radiation, reduced side effects, or improved treatment outcomes.
Pathways that help Radiosensitivity: downregulating HIF-1α, increase SIRT1, Txr

List of Natural Products with radiosensitizing properties:
-Curcumin:modulate NF-κB, STAT3 and has been shown in preclinical studies to enhance the effects of radiation by inhibiting cell survival pathways.
-Resveratrol:
-EGCG:
-Quercetin:
-Genistein:
-Parthenolide:

How radiosensitizers inhibit the thioredoxin (Trx) system in cellular contexts. Notable radiosensitizers, including:
-gold nanoparticles (GNPs),
-gold triethylphosphine cyanide ([Au(SCN) (PEt3)]),
-auranofin, ceria nanoparticles (CONPs),
-curcumin and its derivatives,
-piperlongamide,
-indolequinone derivatives,
-micheliolide,
-motexafin gadolinium, and
-ethane selenide selenidazole derivatives (SeDs)


HNSCC, Head and Neck Squamous Cell Carcinoma: Click to Expand ⟱
Head and Neck Squamous Cell Carcinoma

Scientific Papers found: Click to Expand⟱
5590- BetA,    Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines
- in-vitro, HNSCC, SCC9 - in-vitro, HNSCC, SCC25
RadioS↑,
4522- HNK,  MAG,    Honokiol Is More Potent than Magnolol in Reducing Head and Neck Cancer Cell Growth
- in-vitro, HNSCC, FaDu
AntiCan↑, tumCV↓, eff↑, survivin↓, RadioS↑,
2251- MF,  Rad,    BEMER Electromagnetic Field Therapy Reduces Cancer Cell Radioresistance by Enhanced ROS Formation and Induced DNA Damage
- in-vitro, Lung, A549 - in-vitro, HNSCC, UTSCC15 - in-vitro, CRC, DLD1 - in-vitro, PC, MIA PaCa-2
RadioS↑, DNAdam↑, ROS↑, ChemoSen∅, Pyruv↓, ADP:ATP↓, ROS↑,
2043- PB,  Cisplatin,    Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin
- in-vitro, HNSCC, UM-SCC-1
ChemoSen↑, eff↑, HDAC↓, BRCA1↓, RadioS↑,
4887- ZER,  Rad,  Cisplatin,    Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma
- in-vitro, HNSCC, CAL27
Apoptosis↑, ChemoSen↑, RadioS↑, tumCV↓,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

ROS↑, 2,  

Mitochondria & Bioenergetics

ADP:ATP↓, 1,  

Core Metabolism/Glycolysis

Pyruv↓, 1,  

Cell Death

Apoptosis↑, 1,   survivin↓, 1,  

Transcription & Epigenetics

tumCV↓, 2,  

DNA Damage & Repair

BRCA1↓, 1,   DNAdam↑, 1,  

Proliferation, Differentiation & Cell State

HDAC↓, 1,  

Drug Metabolism & Resistance

ChemoSen↑, 2,   ChemoSen∅, 1,   eff↑, 2,   RadioS↑, 5,  

Clinical Biomarkers

BRCA1↓, 1,  

Functional Outcomes

AntiCan↑, 1,  
Total Targets: 15

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: RadioS, RadioSensitizer
2 Radiotherapy/Radiation
2 Cisplatin
1 Betulinic acid
1 Honokiol
1 Magnolol
1 Magnetic Fields
1 Phenylbutyrate
1 Zerumbone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:13  Cells:%  prod#:%  Target#:1107  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page